Elevated Levels of alpha-2-Heremans-Schmid Glycoprotein in CSF of Patients with Low-Grade Gliomas

Little is known about the expression of mitogens and other tumour-related substances in the cerebrospinal fluid (CSF) of glioma patients. The aim of the current study was to determine the presence of aberrant proteins in the CSF of patients with low-grade gliomas. Lumbar puncture was performed in 8 adult patients with supratentorial low-grade gliomas at the time of diagnosis and in 7 controls. Two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionisation time of flight mass spectrometry were used to detect and quantify deviant proteins in the CSF. Two isoforms of α2-Heremans-Schmid glycoprotein (AHSG) were identified and demonstrated in higher levels in patients with low-grade gliomas compared with the control group consisting of patients with mixed neurological diagnoses (p = 0.001 and p = 0.04, respectively). In 1 patient, the level of AHSG was significantly reduced after gross total resection of the tumour. AHSG appears in the present proteome screening as a novel substance in glioma research. This glycoprotein is expressed in the fetal human brain and is believed to be involved in the embryonic development of the neocortex. Further analyses are planned to determine the significance of the increased levels of AHSG in the CSF of patients with low-grade gliomas.

[1]  C. Wanner,et al.  Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study , 2003, The Lancet.

[2]  L. Kalabay,et al.  Correlation of maternal serum fetuin/alpha2-HS-glycoprotein concentration with maternal insulin resistance and anthropometric parameters of neonates in normal pregnancy and gestational diabetes. , 2002, European journal of endocrinology.

[3]  G. Grunberger,et al.  Plasma alpha2-HS glycoprotein concentrations in patients with acute myocardial infarction quantified by a modified ELISA. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[4]  Danmei Liu,et al.  α2-HS Glycoprotein/Fetuin, a Transforming Growth Factor-β/Bone Morphogenetic Protein Antagonist, Regulates Postnatal Bone Growth and Remodeling* , 2002, The Journal of Biological Chemistry.

[5]  Kaj Blennow,et al.  Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients , 2002, Neuroreport.

[6]  Hao Ding,et al.  Mouse glioma gene expression profiling identifies novel human glioma‐associated genes , 2002, Annals of neurology.

[7]  Å. Haglund,et al.  Phosphorylation of human plasma alpha2-Heremans-Schmid glycoprotein (human fetuin) in vivo. , 2001, The Biochemical journal.

[8]  M. Mann,et al.  Proteomics to study genes and genomes , 2000, Nature.

[9]  U. Lendahl,et al.  Generalized potential of adult neural stem cells. , 2000, Science.

[10]  V. P. Collins,et al.  Progression as exemplified by human astrocytic tumors. , 1999, Seminars in cancer biology.

[11]  Jonas Frisén,et al.  Identification of a Neural Stem Cell in the Adult Mammalian Central Nervous System , 1999, Cell.

[12]  C. Nilsson,et al.  Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis of proteins in human cerebrospinal fluid. , 1998, Rapid communications in mass spectrometry : RCM.

[13]  M. Linskey.  Glial ontogeny and glial neoplasia: The search for closure , 1997, Journal of Neuro-Oncology.

[14]  M Wilm,et al.  Peptide Sequencing by Mass Spectrometry for Homology Searches and Cloning of Genes , 1997, Journal of protein chemistry.

[15]  K. Umetsu,et al.  Molecular evidence for human alpha2-HS glycoprotein (AHSG) polymorphism , 1996, Human Genetics.

[16]  J. Lebreton,et al.  Human inter-alpha-inhibitor family in inflammation: simultaneous synthesis of positive and negative acute-phase proteins. , 1993, The Biochemical journal.

[17]  K. Dziegielewska,et al.  Fetuin ‐ an old friend revisited , 1992, BioEssays : news and reviews in molecular, cellular and developmental biology.

[18]  N. Buchanan,et al.  Liver function tests in persons receiving anticonvulsant medications , 1992, Seizure.

[19]  Anirvan Ghosh,et al.  Requirement for subplate neurons in the formation of thalamocortical connections , 1990, Nature.

[20]  D. Christie,et al.  The complete cDNA and amino acid sequence of bovine fetuin. Its homology with alpha 2HS glycoprotein and relation to other members of the cystatin superfamily. , 1990, The Journal of biological chemistry.

[21]  E. Auerswald,et al.  The arrangement of disulfide loops in human alpha 2-HS glycoprotein. Similarity to the disulfide bridge structures of cystatins and kininogens. , 1989, The Journal of biological chemistry.

[22]  F. Yang,et al.  Human alpha 2-HS-glycoprotein: the A and B chains with a connecting sequence are encoded by a single mRNA transcript. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. Makuch,et al.  Serum glycoproteins in cancer patients: First report of correlations with in vitro and in vivo parameters of cellular immunity , 1980, Cancer.

[24]  S. Chyrek-Borowska.  Serum Glycoproteins , 1963 .

[25]  N. Rawlings,et al.  Evolution of proteins of the cystatin superfamily , 2005, Journal of Molecular Evolution.

[26]  Howard C. Tenenbaum,et al.  alpha 2-HS glycoprotein/fetuin, a transforming growth factor-beta/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. , 2002, The Journal of biological chemistry.

[27]  E. Shaw,et al.  The practical management of low-grade primary brain tumors , 1999 .

[28]  M. Ng,et al.  Selective liver enzyme induction by carbamazepine and phenytoin in Chinese epileptics , 1996, European Journal of Clinical Pharmacology.

[29]  L. Kalabay,et al.  Serum alpha 2-HS glycoprotein concentration in patients with hematological malignancies. A follow-up study. , 1991, Annals of hematology.

[30]  K. Dziegielewska,et al.  A fetuin-related glycoprotein (alpha 2HS) in human embryonic and fetal development. , 1987, Cell and tissue research.

[31]  J. Dobbing.  The development of the blood-brain barrier. , 1968, Progress in brain research.